Inventor · disambiguated record
Julian Bertschinger
Also filed as: BERTSCHINGER JULIAN
9 granted patents·6 pending applications·22 citations·filing 2004–2024
83Inventor score
Top patents by PatentIndex Score
15 records- 0180US10364419B2Human serum albumin binding compounds and fusion proteins thereofCOVAGEN AG·Filed 2017·Granted Jul 30, 2019·3 cites·10 claims
- 0279US9790475B2Human serum albumin binding compounds and fusion proteins thereofCOVAGEN AG·Filed 2013·Granted Oct 17, 2017·4 cites·8 claims
- 0378US9593314B2Binding molecules with antitumoral activityCOVAGEN AG·Filed 2013·Granted Mar 14, 2017·5 cites·10 claims
- 0478US7527954B2Method for in vitro evolution of polypeptidesETH ZUERICH·Filed 2004·Granted May 5, 2009·6 cites·18 claims
- 0570US2025101123A1Multispecific binding molecules comprising ltbr and edb binding domains and uses thereofCILAG GMBH INT·Filed 2024·Application pending·0 cites
- 0666US9085760B2Chymase binding compounds and medical uses thereofBRACK SIMON·Filed 2012·Granted Jul 21, 2015·3 cites·8 claims
- 0758US9315557B2IL-17A binding molecules and medical uses thereofCOVAGEN AG·Filed 2013·Granted Apr 19, 2016·1 cites·18 claims
- 0854US2021188990A1Multispecific binding molecules comprising ltbr and edb binding domains and uses thereofCILAG GMBH INT·Filed 2020·Application pending·0 cites
- 0953US11351267B2FGFR3 binding moleculesCOVAGEN AG·Filed 2020·Granted Jun 7, 2022·0 cites·12 claims
- 1051US10722589B2FGFR3 binding moleculesCOVAGEN AG·Filed 2018·Granted Jul 28, 2020·0 cites·12 claims
- 1142US2017281768A1Novel nucleic acid molecules with antitumoral activityCOVAGEN AG·Filed 2017·Application pending·0 cites
- 1240US2019100587A1IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONSCOVAGEN AG·Filed 2018·Application pending·0 cites
- 1339US9376477B2IL-17 binding compounds and medical uses thereofGRABULOVSKI DRAGAN·Filed 2010·Granted Jun 28, 2016·0 cites·15 claims
- 1439US2016368957A1IL-17 Binding Compounds and Medical Uses ThereofCOVAGEN AG·Filed 2016·Application pending·0 cites
- 1537US2019153096A1Cd3/cd33 bispecific binding moleculesCOVAGEN AG·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →